Technical Analysis for REGN - Regeneron Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 651.88 -0.20% -1.30
REGN closed down 0.2 percent on Friday, September 17, 2021, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical REGN trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Up 3 Days in a Row Strength -0.20%
20 DMA Resistance Bearish -0.02%
Strong but Oversold Other -0.02%
Oversold Stochastic Weakness -0.02%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.04%
Strong but Oversold Other 1.04%
Inside Day Range Contraction 1.04%
Oversold Stochastic Weakness 1.04%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.93%
Older End-of-Day Signals for REGN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Regeneron Pharmaceuticals, Inc. Description

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company's earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: S&P 500 Medicine Biotechnology Biopharmaceutical Nasdaq 100 Immunology Clinical Development Pain Infectious Diseases Antibodies Bone Inflammation Monoclonal Antibodies Clinical Research Disorders Ophthalmology Cardiovascular Disease Macular Degeneration Rheumatoid Arthritis Related Macular Degeneration Asthma Colorectal Cancer Vascular Diseases Cholesterol Cardiovascular Diseases Dermatitis Syndromes Macular Edema Atopic Dermatitis Breakthrough Therapy Related Diseases Lipoprotein Related Disease Cartilage Human Monoclonal Antibodies Metastatic Colorectal Cancer Angiogenesis Regeneron Allergic Asthma Immune Diseases Intravenous Infusion Muscle Disease Muscle Diseases

Is REGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 686.62
52 Week Low 441.0
Average Volume 718,117
200-Day Moving Average 529.99
50-Day Moving Average 623.48
20-Day Moving Average 663.06
10-Day Moving Average 655.52
Average True Range 15.78
ADX 24.42
+DI 17.89
-DI 21.22
Chandelier Exit (Long, 3 ATRs) 639.27
Chandelier Exit (Short, 3 ATRs) 676.28
Upper Bollinger Bands 687.12
Lower Bollinger Band 638.99
Percent B (%b) 0.27
BandWidth 7.26
MACD Line 7.06
MACD Signal Line 12.15
MACD Histogram -5.0949
Fundamentals Value
Market Cap 68.35 Billion
Num Shares 105 Million
EPS 27.29
Price-to-Earnings (P/E) Ratio 23.89
Price-to-Sales 6.24
Price-to-Book 5.26
PEG Ratio 0.96
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 666.45
Resistance 3 (R3) 665.20 659.10 664.02
Resistance 2 (R2) 659.10 655.39 659.72 663.21
Resistance 1 (R1) 655.49 653.10 657.30 656.74 662.40
Pivot Point 649.39 649.39 650.29 650.01 649.39
Support 1 (S1) 645.78 645.68 647.58 647.02 641.36
Support 2 (S2) 639.68 643.39 640.30 640.55
Support 3 (S3) 636.06 639.68 639.74
Support 4 (S4) 637.31